^
    Back
    Association details:
    Biomarker:FLT3‐ITD
    Cancer:Acute Myelogenous Leukemia
    Drug:Xospata (gilteritinib) (Multi-tyrosine kinase inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: B - Late Trials
    Source:
    BSH-I 2020
    Title:

    Gilteritinib prolongs survival in patients with FLT3-mutated relapsed/refractory acute myeloid leukaemia who have common AML co-mutations or a high FLT3–internal tandem duplication allelic ratio

    Published date:
    01/05/2021
    Excerpt:
    The ADMIRAL trial shows that the clinical benefit of gilteritinib in FLT3‐mutated relapsed/refractory AML….gilteritinib conferred longer overall survival than salvage chemotherapy in patients with a high or low FLT3‐ITD allelic ratio....overall survival was longer in the low FLT3‐ITD allelic ratio cohort than the high FLT3‐ITD allelic ratio cohort...